Conference call agenda FY and Q4 2025 Results Conference call and webcast for investors and analysts 10 February 2026 Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial conditi ...

Core Insights - Regeneron Pharmaceuticals, Inc. reported Q4 2025 results with revenue of $3.9 billion, a 3.0% increase year over year, exceeding consensus expectations by approximately 3% [1] - Adjusted EPS for the quarter reached $11.44, which is 7% above street expectations, indicating strong profitability [1] - The company's performance is driven by four blockbuster medicines and a promising late-stage clinical portfolio, with significant label expansions and new solutions for EYLEA HD [1] Financial Performance - Q4 revenue was $3.9 billion, reflecting a 3.0% year-over-year growth [1] - Adjusted EPS for Q4 was $11.44, exceeding expectations by 7% [1] - BofA Securities projected Q4 collaboration revenues from Sanofi at $1.6 billion, a 32% increase year over year, while Bayer collaboration revenues were estimated at $361 million, down 4% year over year [3] Product Developments - EYLEA HD received label expansions, enhancing its commercial potential [1] - Dupixent has new approvals in Japan and Europe, with over 1.4 million active patients globally, making it the most widely used innovative branded antibody medicine [1] - Libtayo secured additional approvals and remains a leading immunotherapy for non-melanoma skin cancers [1] Analyst Ratings and Projections - BofA Securities maintained a Buy rating with a price target of $860, incorporating the impact of R&D estimates and other disclosures [2] - Evercore ISI raised the price target to $875 from $750, reiterating an Outperform rating, emphasizing Dupixent's growth and Eylea HD's competitive prospects [4] - For 2026, BofA estimated U.S. Eylea franchise revenues at $4.43 billion, higher than previous forecasts and consensus [3]